ClearPoint Neuro, Inc. Cash Flow Statement
CLPT|14 years of annual SEC 10-K data (FY2012-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$24M
FY2025
Free Cash Flow
-$24M
FY2025
Capital Expenditures
$522,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
ClearPoint Neuro, Inc. used $24M in operating cash flow and negative free cash flow of $24M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$25.5M | -$22.1M | -$22.1M | -$16.4M | -$14.4M | -$6.8M | -$5.5M | -$6.2M | -$7.2M | -$8.1M | -$8.4M | -$4.5M | -$5.9M | -$5.9M |
| Depreciation & Amortization | $814.0K | $626.0K | $626.0K | $244.0K | $159.0K | $334.0K | $144.0K | $109.4K | $116.5K | $155.7K | $211.9K | $377.3K | $417.0K | $417.0K |
| Operating Cash Flow | -$23.9M | -$13.7M | -$13.7M | -$16.2M | -$12.7M | -$7.8M | -$2.9M | -$4.6M | -$6.0M | -$5.8M | -$8.6M | -$7.3M | -$7.4M | -$7.4M |
| Capital Expenditures | $522.0K | $717.0K | $717.0K | $253.0K | $168.0K | $41.0K | $10.0K | $63.5K | $26.8K | $101.0K | $76.9K | $48.1K | $127.5K | $127.5K |
| Free Cash Flow | -$24.4M | -$14.4M | -$14.4M | -$16.4M | -$12.9M | -$7.8M | -$2.9M | -$4.7M | -$6.0M | -$5.9M | -$8.7M | -$7.3M | -$7.6M | -$7.6M |
| FCF Margin | -66.1% | -60.3% | -60.3% | -79.9% | -78.9% | -61.2% | -25.5% | -63.8% | -81.6% | -103.0% | -189.7% | -202.5% | -149.5% | -149.5% |